Australia (AU)

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

The Palgrave Handbook of Ageing and Physical Activity Promotion (2018) Nyman SR, Barker A, Haines T, Horton K, Musselwhite C, Peeters G, Victor CR, Wolff JK Authored book, Monography rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Fasching P, Beckmann M, Ekici AB, et al. Journal article The sacral autonomic outflow: against premature oversimplification (2018) Jaenig W, Mclachlan EM, Neuhuber W Journal article Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients (2018) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa A, Combe B, Rech J, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study (2018) Mcinnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS (2018) Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, et al. Conference contribution NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY (2018) Lopez-Isac E, Acosta-Herrera M, Assassi S, Simeon CP, Carreira PE, Castellvi I, Ortego-Centeno N, et al. Conference contribution Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis (2018) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution